These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28175315)

  • 1. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    Naidoo A; Chirehwa M; McIlleron H; Naidoo K; Essack S; Yende-Zuma N; Kimba-Phongi E; Adamson J; Govender K; Padayatchi N; Denti P
    J Antimicrob Chemother; 2017 May; 72(5):1441-1449. PubMed ID: 28175315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.
    Habtewold A; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Burhenne J; Aklillu E
    Pharmacogenomics; 2015; 16(10):1047-64. PubMed ID: 25831219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old.
    Kwara A; Yang H; Antwi S; Enimil A; Gillani FS; Dompreh A; Ortsin A; Opoku T; Bosomtwe D; Sarfo A; Wiesner L; Norman J; Alghamdi WA; Langaee T; Peloquin CA; Court MH; Greenblatt DJ
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
    Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P;
    J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
    Friedland G; Khoo S; Jack C; Lalloo U
    J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
    Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa.
    Cohen K; Grant A; Dandara C; McIlleron H; Pemba L; Fielding K; Charalombous S; Churchyard G; Smith P; Maartens G
    Antivir Ther; 2009; 14(5):687-95. PubMed ID: 19704172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.
    Mukonzo JK; Nanzigu S; Waako P; Ogwal-Okeng J; Gustafson LL; Aklillu E
    Pharmacogenomics; 2014 Aug; 15(11):1423-35. PubMed ID: 25303294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
    Kwara A; Lartey M; Sagoe KW; Xexemeku F; Kenu E; Oliver-Commey J; Boima V; Sagoe A; Boamah I; Greenblatt DJ; Court MH
    J Clin Pharmacol; 2008 Sep; 48(9):1032-40. PubMed ID: 18728241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
    Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
    Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
    Podany AT; Pham M; Sizemore E; Martinson N; Samaneka W; Mohapi L; Badal-Faesen S; Dawson R; Johnson JL; Mayanja H; Lalloo U; Whitworth WC; Pettit A; Campbell K; Phillips PPJ; Bryant K; Scott N; Vernon A; Kurbatova EV; Chaisson RE; Dorman SE; Nahid P; Swindells S; Dooley KE; Fletcher CV
    Clin Infect Dis; 2022 Sep; 75(4):560-566. PubMed ID: 34918028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy.
    Lee KY; Lin SW; Sun HY; Kuo CH; Tsai MS; Wu BR; Tang SY; Liu WC; Chang SY; Hung CC
    PLoS One; 2014; 9(2):e88497. PubMed ID: 24551111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ;
    Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.
    Mukonzo JK; Okwera A; Nakasujja N; Luzze H; Sebuwufu D; Ogwal-Okeng J; Waako P; Gustafsson LL; Aklillu E
    BMC Infect Dis; 2013 Jun; 13():261. PubMed ID: 23734829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early or deferred initiation of efavirenz during rifampicin-based TB therapy has no significant effect on CYP3A induction in TB-HIV infected patients.
    Aklillu E; Zumla A; Habtewold A; Amogne W; Makonnen E; Yimer G; Burhenne J; Diczfalusy U
    Br J Pharmacol; 2021 Aug; 178(16):3294-3308. PubMed ID: 33155675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of efavirenz-based ART on the pharmacokinetics of rifampicin and its primary metabolite in patients coinfected with TB and HIV.
    Sundell J; Bienvenu E; Äbelö A; Ashton M
    J Antimicrob Chemother; 2021 Oct; 76(11):2950-2957. PubMed ID: 34337654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.